# Study of Rifampicin in Multiple System Atrophy

> **NCT01287221** · PHASE3 · TERMINATED · sponsor: **Phillip Low** · enrollment: 100 (actual)

## Conditions studied

- Multiple System Atrophy

## Interventions

- **DRUG:** Rifampicin
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01287221
- **Lead sponsor:** Phillip Low
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-03
- **Primary completion:** 2012-11
- **Final completion:** 2013-01
- **Target enrollment:** 100 (ACTUAL)
- **Why stopped:** DSMB recommended stopping the study after an interim analysis of the primary endpoint revealed that futility criteria were met.
- **Last updated:** 2014-03-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01287221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01287221, "Study of Rifampicin in Multiple System Atrophy". Retrieved via AI Analytics 2026-06-21 from https://api.ai-analytics.org/clinical/NCT01287221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*